OpenAI Introduces GPT‑Rosalind for Life Sciences Research

OpenAI has unveiled GPT‑Rosalind, a new AI model purpose-built for life sciences research, according to an announcement on its website. The model is designed to assist researchers working in biology, drug discovery, and translational medicine by improving reasoning and tool use across complex scientific workflows.

GPT‑Rosalind is available as a research preview through ChatGPT, Codex, and the API for qualified customers under a trusted access program. It includes a Life Sciences research plugin for Codex that connects to more than 50 scientific tools and data sources, enabling workflows such as literature review, protein structure analysis, and experimental design.

In internal evaluations, GPT‑Rosalind outperformed previous models on benchmarks covering chemistry, protein engineering, and genomics tasks. The model also achieved top results on BixBench and LABBench2, which test bioinformatics and experimental design capabilities. OpenAI is collaborating with organizations including Amgen, Moderna, Thermo Fisher Scientific, and the Allen Institute to apply the model to real-world research.

The company stated that GPT‑Rosalind was developed with enterprise-grade security and controlled access to ensure safe use in scientific environments. During the research preview, qualified organizations can request access without credit consumption, with broader availability planned as the program expands.